

# Jun-Ling Li

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5918250/jun-ling-li-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38  
papers

241  
citations

7  
h-index

14  
g-index

40  
ext. papers

379  
ext. citations

4  
avg, IF

3.36  
L-index

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 38 | Apatinib as maintenance therapy following standard first-line chemotherapy in extensive disease small cell lung cancer: A phase II single-arm trial.. <i>Thoracic Cancer</i> , <b>2022</b> ,  | 3.2  | 1         |
| 37 | Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study.. <i>BMC Medicine</i> , <b>2022</b> , 20, 12  | 11.4 | 2         |
| 36 | Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study.. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2022</b> , 1  | 4.9  | 1         |
| 35 | Specific Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to -Targeted Tyrosine Kinase Inhibitors.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 806737  | 5.6  | 1         |
| 34 | Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (-TKI) in -Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients.. <i>Cancer Management and Research</i> , <b>2022</b> , 14, 863-873                             | 3.6  | 0         |
| 33 | Clinical significance of ALDH1A1 expression and its association with E-cadherin and N-cadherin in resected large cell neuroendocrine carcinoma.. <i>Translational Oncology</i> , <b>2022</b> , 19, 101379   | 4.9  |           |
| 32 | Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis.. <i>BMC Cancer</i> , <b>2022</b> , 22, 514   | 4.8  | 1         |
| 31 | Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 3407   | 3.2  | 2         |
| 30 | Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China. <i>Thoracic Cancer</i> , <b>2021</b> ,   | 3.2  | 1         |
| 29 | ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer. <i>Molecular Medicine</i> , <b>2021</b> , 27, 138  | 6.2  | 2         |
| 28 | Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: A comprehensive analysis of 358 patients. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 1943-1951   | 3.2  | 3         |
| 27 | Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 2233-2240 | 3.2  | 1         |
| 26 | Clinicopathological features and prognostic analysis of 247 small cell lung cancer with limited-stage after surgery. <i>Human Pathology</i> , <b>2021</b> , 108, 84-92  | 3.7  | 1         |
| 25 | Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 40-47  | 3.2  | 2         |
| 24 | Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC). <i>Thoracic Cancer</i> , <b>2021</b> , 12, 2360-2368  | 3.2  | 1         |
| 23 | Pyrotinib in HER2 heterogeneously mutated or amplified advanced non-small cell lung cancer patients: a retrospective real-world study (PEARL). <i>Journal of the National Cancer Center</i> , <b>2021</b> , 1, 139-139  |      | 2         |
| 22 | Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 2825-2828   | 3.2  | 3         |

|    |  |      |    |
|----|--|------|----|
| 21 | Aperture: alignment-free detection of structural variations and viral integrations in circulating tumor DNA. <i>Briefings in Bioinformatics</i> , <b>2021</b> , 22,  | 13.4 | 1  |
| 20 | Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 2585-2593                       | 3.2  | 2  |
| 19 | Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 2924-2932  | 3.2  | 2  |
| 18 | YAP1 protein expression has variant prognostic significance in small cell lung cancer (SCLC) stratified by histological subtypes. <i>Lung Cancer</i> , <b>2021</b> , 160, 166-174  | 5.9  | 2  |
| 17 | Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis.. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2021</b> , 2021, 9311875                | 2.3  | 3  |
| 16 | ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.. <i>Thoracic Cancer</i> , <b>2021</b> ,                   | 3.2  | 1  |
| 15 | Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2020</b> , 146, 2427-2433   | 4.9  | 19 |
| 14 | Comparative study of clinicopathological characteristics and prognosis between combined and pure small cell lung cancer (SCLC) after surgical resection. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 2782-2792                                      | 3.2  | 10 |
| 13 | Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib. <i>Targeted Oncology</i> , <b>2019</b> , 14, 335-342  | 5    | 19 |
| 12 | Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1461-1468  | 3.2  | 7  |
| 11 | Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1213-1219  | 3.2  | 2  |
| 10 | Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China. <i>Targeted Oncology</i> , <b>2019</b> , 14, 325-333                                    | 5    | 3  |
| 9  | Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis. <i>Clinical and Translational Oncology</i> , <b>2019</b> , 21, 1424-1431                               | 3.6  | 13 |
| 8  | Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis <b>2019</b> , 7, 341   |      | 74 |
| 7  | Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 9243-9251  | 3.6  | 8  |
| 6  | Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants. <i>Lung Cancer</i> , <b>2018</b> , 118, 128-133  | 5.9  | 33 |
| 5  | Evaluation of calculating carboplatin dosage in carboplatin-pemetrexed therapy as the first-line therapy for Chinese patients with advanced lung adenocarcinoma. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 400-407                                 | 3.2  | 3  |
| 4  | Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 1716-1724 | 3.2  | 1  |

|   |  |     |   |
|---|--|-----|---|
| 3 | Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 805-813           | 3.2 | 3 |
| 2 | Gemcitabine combined with cisplatin as adjuvant chemotherapy for non-small cell lung cancer: A retrospective analysis. <i>Thoracic Cancer</i> , <b>2017</b> , 8, 482-488                           | 3.2 | 5 |
| 1 | P3.04-007 A Prospective Study of Apatinib in Advanced Small Cell Lung Cancer Patients Failed from Two or More Lines of Chemotherapy. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, S2287 | 8.9 | 5 |